(Q34294886)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11428998%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

review article

1 reference

title

Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11428998%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11428998%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

M Tiphine

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11428998%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

V Letscher-Bru

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11428998%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 December 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11428998%20AND%20SRC:MED&resulttype=core&format=json

Transplant Infectious Disease

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11428998%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11428998%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11428998%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

273-283

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11428998%20AND%20SRC:MED&resulttype=core&format=json

How do the polyene macrolide antibiotics affect the cellular membrane properties?

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Transfer of amphotericin B from gel state vesicles to mycoplasma cells: biphasic action on potassium transport and permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

AmBisome (liposomal amphotericin B): a comparative review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Comparative Safety, Tolerance, and Pharmacokinetics of Amphotericin B Lipid Complex and Amphotericin B Desoxycholate in Healthy Male Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Amphotericin B Pharmacokinetics in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Clinical pharmacokinetics of systemic antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Lipid formulations of amphotericin B: clinical efficacy and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Administering amphotericin B--a practical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Treatment of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Survival factors in rhino-orbital-cerebral mucormycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Pretreatment regimens for adverse events related to infusion of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Efficacy of nefopam for the prevention and treatment of amphotericin B-induced shivering.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Rapid Infusion of Amphotericin B in Dextrose

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Rapid intravenous infusion of amphotericin B: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Sodium status influences chronic amphotericin B nephrotoxicity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Amphotericin B nephrotoxicity in humans decreased by salt repletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Effect of salt supplementation on amphotericin B nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Must we really fear toxicity of conventional amphotericin B in oncological patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Effect of mannitol on acute amphotericin B nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Amphotericin B intralipid formulation: stability and particle size

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Overview of amphotericin B colloidal dispersion (amphocil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Safety and efficacy of amphotericin B colloidal dispersion. An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Safety of amphotericin B colloidal dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Renal sparing by amphotericin B colloidal dispersion: clinical experience in 572 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Tissue Distribution of Amphotericin B Lipid Complex in Laboratory Animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Amphotericin B lipid complex therapy of experimental fungal infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Liposomal amphotericin B, AmBisome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Clinical use of liposomal and lipid-complexed amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Trichosporon beigelii, an emerging pathogen resistant to amphotericin B

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Serum pharmacology of amphotericin B applied in lipid emulsions.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Distribution and activity of amphotericin B in humans

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Amphotericin-induced heart-rate decrease in children

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Chronic Amphotericin B Nephrotoxicity in the Rat, Protective Effect of Prophylactic Salt Loading

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Amphotericin B does not mix with fat emulsion

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Successful treatment of visceral leishmaniasis with high-dose amphotericin B diluted in fat emulsion: a case report

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010406.X

7 January 2021

10.1034/J.1399-3062.1999.010406.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11428998%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference